The pharmaceutical industry, with public health officials and
the mainstream media acting as a mass marketing team, is about
to pull off the biggest profiteering scheme in the history of
the world. The swine flu hoax, perpetrated on a global level,
will generate unheard of profits from a non-existent pandemic.

The Obama administration declared the spread of swine flu a public
health emergency on April 26, 2009. The Associated Press reported
that "Swine flu is now formally a pandemic, a declaration
by U.N. health officials that will speed vaccine production and
spur government spending to combat the first global flu epidemic
in 41 years," on June 11, 2009.

"WHO chief Dr. Margaret Chan made the long-awaited declaration
after the U.N. agency held an emergency meeting with flu experts
and said she was moving to phase 6 -- the agency's highest alert
level -- which means a pandemic is under way," the AP advised.

Since the "highest alert" warning was issued, the only
estimation that has turned out to be true is that the drug companies
are experiencing a windfall of tax dollars pouring into their
coffers.

The US government "has committed $1.8 billion to companies
to make a swine flu vaccine," Reuters reported on September
30, 2009, in an article with the headline, "Big pharma jumps
back into flu business."

"Three big U.S. pharmaceutical companies announced vaccine
deals this week," Reuters noted, for companies that included
Johnson & Johnson, Abbott Laboratories and Merck.

"Abbott Labs bought a Belgian drug business, along with
its flu vaccine facilities, for $6.6 billion. Johnson & Johnson
invested $444 million in a Dutch biotech firm (Crucell) that makes
and develops flu vaccines. Merck which already makes vaccines
for shingles and other diseases, struck a deal to distribute flu
shots made by Australian CSL," ABC News reported on October
14, 2009

"Smaller biotechs are also angling for a slice of the action,
making vaccines one of the fastest-growing areas of research in
the biotech industry," ABC noted.

Dr Robert Belshe, director of Saint Louis University's Center
for Vaccine Development, told Reuters that the US is on the verge
of recommending that all citizens get a flu shot. "We're
at 270 million people who should get vaccinated. It's a big market.
I think manufacturers are just now catching up," he said.

"The vaccine market is booming. It's an enormous growth
area for pharmaceuticals at a time when other areas are not doing
so well," Bruce Carlson, a spokesperson for the market research
firm Kalorama, told ABC News.

On October 1, 2009, under the headline, "Vical shares soar
on Navy's H1N1 contract," Fierce Vaccines advised that: "Anyone
doubting just how hot H1N1 news is right now should check out
Vical's stock price this morning."

"The developer announced a modest $1.3 million contract
with the Navy to fund the manufacturing and testing of its swine
flu vaccine and the company's stock shot up 22 percent,"
the report said.

On September 29, 2009, Reuters noted that the H1N1 flu pandemic
is not "the first flu outbreak to have lifted the shares
of small vaccine makers."

"The H5N1 bird flu scare that began in 2005 fueled a similar
rise," the reports said. "And the media statements issued
by companies then are similar to many of those issued today."

"In May 2006, Vical, for example, announced that its bird
flu vaccine protected mice and ferrets against H5N1," Reuters
recalled.

"This year, it said its H1N1 pandemic flu vaccine protected
rabbits and mice. The news sent its shares soaring," the
report noted.

Vaccine Makers Fund Studies

On September 10, 2009, MedPage Today ran the headline: "H1N1
Vaccines Safe, Immunogenic in Single Dose".

"Two investigational vaccines against the pandemic H1N1
flu appear to be safe and to yield a robust immune response with
a single dose," MedPage reported.

"Those findings," it said, "contained in two preliminary
reports published online today in the New England Journal of Medicine
-- are reassuring, experts said."

The first report is from an Australian study supported by CSL
and the Department of Health and Aging of the Australian government.
"All authors report being employees of CSL and several report
having an equity interest in the company," according to MedPage.

The second report is from a British study supported by University
Hospitals Leicester and Novartis. Study leader, Dr Iain Stephenson,
"reported financial links with Novartis Vaccines, Sanofi
Pasteur, Baxter Vaccines, HoffmannLa Roche, and GlaxoSmithKline,"
MedPage noted.

Profits Galore

On September 21, 2009, Reuters reported that the United States
had ordered 222 million doses of H1N1 vaccine from five drug makers
that include GlaxoSmithKline, Sanofi-Pasteur, Australia's CSL,
AstraZeneca's MedImmune division and Novartis.

CSL has contracts to supply $180 million worth of bulk antigen
to the US. Sanofi-Pasteur is providing more than 100 million doses
to the US, in a $690 million order.

On September 25, 2009, MedImmune said it has "received a
federal order for 29 million more doses of its nasal H1N1 flu
vaccine, bringing its total order to more than 40 million doses,
with a value of about $453 million," according to Gazette.net.

Seeking Alpha reported on August 24, 2009, that the "Swiss
company Novartis received an order for $346 million for antigen
and $343.8 million for adjuvant totalling $690 million in July."

The most recent estimates have GlaxoSmithKline "reaping
some $4.8 billion from the pandemic, between its Pandemrix vaccine,
its Relenza antiviral drug, and other products such as antiviral
face masks and flu diagnostics," Fierce Pharma reported on
October 9, 2009.

On June 11, 2009, Kalorama Information issued a press release
with the headline, "New Report Forecasts More Than Doubling
of Vaccine Sales by 2013."

The new report titled, "Vaccines 2009: World Market Analysis,
Key Players, and Critical Trends in a Fast-Changing Industry,"
forecasts the market "to more than double by 2013 due to
a strong pipeline of new products and rising usage of current
products around the world," Kalorama wrote.

In the press release, Kalorama described 2008 as another "stellar
year for the world vaccine market," in which sales "grew
21.5% since 2007 to reach $19.2 billion."

"Few areas of pharmaceuticals have seen the fast-moving
developments in the marketplace that the vaccine market has,"
Kalorama noted.

Antiviral Drug Hype

On October 15, 2009, the Financial Times ran the headline: "Tamiflu
boosts Roche sales figures," and reported that sales figures
"were boosted by bumper demand for Tamiflu amid persistent
fears about a global flu pandemic."

Tamiflu sales of $1.9 billion in the first nine months were more
than four times ahead of the same period last year and third quarter
sales figures were "nearly 10 times more than in the same
period last year."

On July 22, 2009, Business Week reported that GlaxoSmithKline
"expects to increase annual production of its inhalable anti-viral
flu treatment Relenza threefold, to 190 million doses, by year
end."

"Relenza sales for the three months ended June 30 were $99
million, up from just $5 million in the second quarter of 2008,"
the report noted.

The price of Tamiflu at a middle dose at DrugStore.com on August
26, 2009, was $93 for a packet of ten 75mg capsules. One inhaler
of Relenza costs $64 at DrugStore.com.

Any good that will come from the swine flu propaganda campaign
will accumulate solely with the profits of pharmaceutical industry.